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A S SOC I AT I ON STUD I E S ART I C L E
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Abstract
Infantile hypertrophic pyloric stenosis (IHPS) is a disorder of young infants with a population incidence of ∼2/1000 live
births, caused by hypertrophy of the pyloric sphincter smooth muscle. Reported genetic loci associated with IHPS explain
only a minor proportion of IHPS risk. To identify new risk loci, we carried out a genome-wide meta-analysis on 1395
surgery-confirmed cases and 4438 controls, with replication in a set of 2427 cases and 2524 controls. We identified and
replicated six independent genomic loci associated with IHPS risk at genome wide significance (P < 5 × 10−8), including
novel associations with two single nucleotide polymorphisms (SNPs). One of these SNPs, rs6736913 [odds ratio (OR) = 2.32;
P = 3.0 × 10−15], is a low frequency missense variant in EML4 at 2p21. The second SNP, rs1933683 (OR = 1.34; P = 3.1 × 10−9)
is 1 kb downstream of BARX1 at 9q22.32, an essential gene for stomach formation in embryogenesis. Using the genome-wide
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complex trait analysis method, we estimated the IHPS SNP heritability to be 30%, and using the linkage disequilibrium score
regression method, we found support for a previously reported genetic correlation of IHPS with lipid metabolism.
By combining the largest collection of IHPS cases to date (3822 cases), with results generalized across populations of
different ancestry, we elucidate novel mechanistic avenues of IHPS disease architecture.
Introduction
Infantile hypertrophic pyloric stenosis (IHPS), first described by
the Danish pediatrician Dr Harald Hirschsprung in 1888 (1), is a
serious condition of young infants caused by hypertrophy of the
pyloric sphincter smooth muscle, which can lead to obstruction
of the gastric outlet and consequent projectile vomiting. The
only definitive treatment is pyloromyotomy, a surgical procedure
first described by Ramstedt in 1912 (2), in which an incision of
the pyloric muscle is made to relieve its constriction and allow
the contents of the stomach to pass to the duodenum. IHPS has
an incidence of 2 to 5 per 1000 live births among individuals
of European ancestry, with a 4- to 5-fold higher risk in boys
than in girls (3). Several studies have suggested that exposure
to medications and perinatal factors may be associated with the
development of IHPS, such as use of macrolide antibiotics (4),
being first-born, delivery by cesarean section, preterm birth and
bottle feeding (5).Moreover, sharp changes in reported incidence
of IHPS in Europe (6) emphasize the importance of modifiable
environmental exposures on the risk of IHPS. Nevertheless, its
familial aggregation of 20-fold increased risk among siblings,
heritability estimates of 87% (7) and co-occurrence with multi-
ple genetic syndromes (8) suggest a strong genetic component
for IHPS.
Two genome-wide association studies (GWAS) of IHPS have
been published, both by our group, in which we identified four
genome-wide significant risk loci near themuscleblind-like splicing
regulator 1 gene, the NK2 homeobox 5 gene (NKX2-5) and the
apolipoprotein A-I (APOA1) gene (9,10). However, these four loci
only explain a modest proportion of IHPS heritability.
In the present study, we report the largest investigation to
date of the influence of common and low frequency genetic
variation on IHPS risk by doing a genome-wide meta-analysis
of our previous GWAS cohort (9,10), with an additional 427
surgery-confirmed cases and 2031 controls, all from Denmark.
The results were replicated in 1794 cases and 1875 controls of
European ancestry and further confirmed in 633 cases and 633
controls from a Hispanic population.
Results
Study subjects
In order to identify IHPS susceptibility loci we did a genome-
wide meta-analysis of two IHPS case-control cohorts, all
of Danish ancestry, in which the IHPS cases were surgery-
confirmed singletons without major congenital malformations
(see Materials and Methods).
Genome-wide meta-analysis confirms four known loci
and detects two additional independent loci
After applying quality control measures and performing HRC
imputation (20), the meta-analysis included a total of 1395 cases
and 4438 controls at 6 576 307 autosomal single nucleotide poly-
morphisms (SNPs) (MAF> 1%, r2 imputation info score≥ 0.8).Our
meta-analysis showed a genomic inflation of 1.10 (Supplemen-
tary Material, Fig. S1). However, the linkage disequilibrium (LD)
score regression intercept was 1.02, suggesting that the majority
of the inflation in test statistics was attributable to the polygenic
architecture of IHPS, rather than population stratification or
cryptic relatedness (25,36).
In the discovery phase analysis, we identified eight genome-
wide significant loci (P< 5× 10−8) (Fig. 1; Table 1; Supplementary
Material, Table S1 and 2; Figs S2–9), and conditioning on the top
SNP at each locus did not reveal secondary signals (Supplemen-
tary Material, Figs S2–9). No heterogeneity was found between
the two IHPS discovery phase cohorts (Cochran’s Q test, P > 0.2;
Table 1) for the genome-wide significant loci. Among the eight
loci that were genome-wide significant, four on chromosomes
3q25.1, 3q25.2, 5q35.1 and 11q23.3 were previously associated
with IHPS (9,10), whereas the remaining four on chromosomes
2p21, 3p14.3, 9q22.32 and 13q21.31 have not previously been
reported (Table 1; Fig. 1; Supplementary Material, Tables S1 and
2; Figs S2–9).
At the known locus on 5q35.1 near NKX2-5, we identified
a more significantly associated SNP (Supplementary Material,
Table S2). While the previously reported top SNP rs29784,
downstream of BNIP1, had a meta-analysis P = 1.37 × 10−15,
this study’s top SNP rs9313619, intergenic, has a meta-analysis
P = 3.80 × 10−21. Moreover, rs9313619 remained genome-
wide significant when conditioning on rs29784 (conditional
P = 3.50 × 10−8), while if conditioning on rs9313619, the
previously reported top SNP rs29784 remained only nominally
significant (P = 0.02). Of note, rs9313619 is in a repeat region
with significant homology to other regions of the genome,
and we, therefore, selected the SNP rs6556059 (r2 = 0.92 with
rs9313619) for replication phase genotyping. The SNP rs6556059
is an expression quantitative trait loci (eQTL) for NKX2-5 in skin
and heart (atrial appendage), as assessed in adult tissues from
the Genotype-Tissue Expression (GTEx) Consortium project (35),
with the IHPS risk allele associated with increased expression
of NKX2-5. Conditional analyses at 3q25.1, 3q25.2 and 11q23.3
suggest that the previously reported top SNPs remain as such in
this study.
Two new IHPS loci on chromosomes 2p21 and 9q22.32 were
confirmed in the replication phase analyses, while the loci on
3p14.3 and 13q21.31 were not (Table 1; Supplementary Material,
Tables S1 and 2). The new IHPS locus with the strongest effect
size was located on chromosome 2p21. Its top SNP rs34216221,
intronic inMTA3, had an odds ratio (OR) of 2.53 (P = 4.97 × 10−14,
Fig. 2A) in our discovery phase meta-analysis and a risk allele
frequency of 0.01 in the 1000 Genomes European population
(37). The GWAS significant SNPs on this locus span the genes
EML4, COX7A2L, KCNG3, MTA3, OXER1 and HAAO, of which
EML4 and MTA3 show the highest levels of Histone H3 tri-
methyl K36 (H3K36me3) marks in fetal and adult stomach
and small intestine (Supplementary Material, Fig. S10), which
are marks known to be associated with actively transcribed
regions (33). If the top choice variant for replication was in a
repeat region or had non-uniquely mapped flanking sequence
to the human genome, we chose an alternative variant with
high LD (r2 > 0.8) with the top one (see Materials and Methods).
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Figure 1. Manhattan plot of the IHPS genome-wide association meta-analysis in the discovery cohort (1395 cases and 4438 controls; Denmark).
Table 1. Association results with IHPS in discovery (Denmark), replication (Sweden and US—non-Hispanic Whites) and combined analysis
Alleles Frequency Number
SNP Position A1 A2 Cohort Cases Controls Cases Controls OR (95% CI) P Q
rs6736913 2:42510018 A G Discovery 0.045 0.019 1395 4438 2.42 (2.17–2.68) 4.79E-12 0.6215
United States 0.024 0.012 1671 1685 1.98 (1.59–2.37) 5.82E-04 0.0532
Sweden 0.031 0.006 113 177 5.78 (4.19–7.37) 3.06E-02 -
Combined 0.033 0.017 3179 6300 2.32 (2.11-2.53) 3.00E-15 0.1992
rs7644486 3:57869963 C T Discovery 0.319 0.260 1395 4438 1.32 (1.23–1.41) 5.34E-09 0.4966
United States 0.303 0.287 1677 1693 1.08 (0.98–1.19) 1.44E-01 0.3867
Sweden 0.292 0.297 113 177 0.98 (0.61–1.35) 9.05E-01 -
Combined 0.309 0.268 3185 6308 1.20 (1.13–1.27) 1.83E-07 0.0370
rs11712066 3:151830309 G A Discovery 0.171 0.252 1395 4438 0.62 (0.52–0.73) 3.73E-17 0.7899
United States 0.148 0.209 1671 1676 0.65 (0.53–0.78) 8.29E-11 0.9453
Sweden 0.161 0.231 112 175 0.62 (0.16–1.07) 3.54E-02 -
Combined 0.159 0.240 3178 6289 0.64 (0.55–0.72) 2.57E-27 0.9840
rs573872 3:153472163 G T Discovery 0.280 0.225 1395 4438 1.33 (1.23–1.43) 7.74E-09 0.2193
United States 0.241 0.203 1671 1684 1.24 (1.12–1.35) 2.90E-04 0.0522
Sweden 0.336 0.214 113 175 1.88 (1.49–2.26) 1.42E-03 -
Combined 0.261 0.219 3179 6297 1.31 (1.24–1.38) 4.96E-13 0.0455
rs6556059 5:172645766 T C Discovery 0.452 0.355 1395 4438 1.50 (1.41–1.59) 4.24E-19 0.5220
United States 0.426 0.343 1667 1680 1.42 (1.32–1.52) 4.27E-12 0.9360
Sweden 0.474 0.334 113 175 1.79 (1.44–2.14) 1.10E-03 -
Combined 0.439 0.351 3175 6293 1.48 (1.41–1.54) 1.49E-31 0.6910
rs1933683 9:96712771 G C Discovery 0.131 0.094 1395 4438 1.50 (1.36–1.64) 4.58E-09 0.8138
United States 0.139 0.120 1671 1685 1.22 (1.10–1.34) 1.17E-03 0.5543
Sweden 0.170 0.127 112 177 1.40 (0.93–1.87) 1.58E-01 -
Combined 0.136 0.102 3178 6300 1.34 (1.24–1.43) 3.05E-09 0.1920
rs12721025 11:116706047 A G Discovery 0.087 0.058 1395 4438 1.58 (1.42–1.74) 4.12E-08 0.8483
United States 0.087 0.069 1667 1671 1.27 (1.09–1.45) 9.39E-03 0.0318
Sweden 0.097 0.051 113 175 2.03 (1.37–2.69) 3.56E-02 -
Combined 0.087 0.061 3175 6284 1.45 (1.33–1.57) 1.07E-09 0.0691
SNP, dbSNP v146 variant ID; Position, hg19 human genome assembly; A1, effect allele; A2, alternative allele; Frequency, effect allele frequency; odds ratio [OR; 95%
confidence interval (CI)], OR of the effect allele (95% CI); P, fixed-effects meta-analysis P-value; Q, P-value for Cochrane’s Q statistic (measure of heterogeneity). All
specimens are of European ancestry.
In meta-analyzed replication results, we genotyped the SNP
rs6736913, a missense variant in the EML4 gene on chromosome
2p21 (NM 019063.4:c.847G>A; NP 061936.2:p.Glu283Lys), and
observed an OR for IHPS of 2.10 (P = 1.15 × 10−4) (Table 1;
Supplementary Material, Table S1) . When the results from
the discovery and replication phases were meta-analyzed, the
summary OR for IHPS was 2.32 (P = 3.00 × 10−15) for rs6736913
on 2p21 EML4-MTA3 locus (Table 1; Supplementary Material,
Table S1).
The other novel IHPS locus was found on chromosome
9q22.32. Here, the lead SNP rs1933683, downstream of BARX1,
had an OR of 1.50 (P = 4.58 × 10−9, Fig. 2B) in our discovery phase
meta-analysis and a risk allele frequency of 0.13 in the 1000
Genomes European population (37). The GWAS significant SNPs
at this locus cover the BARX1 (BARX homeobox 1) gene encoding
a homeodomain transcription factor. Among the adult GTEx
tissues (37), BARX1 is predominantly expressed in the stomach
and the gastroesophageal junction (Supplementary Material,
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Figure 2. Regional association plots of the new genome-wide significant loci for IHPS. (A) Association results at the 2p21 EML4-MTA3 locus. (B) Association results at
the 9q22.32 BARX1 locus. Color-coded LD is shown for the top SNP at each locus (LD determined with our discovery phase cohorts). The x-axis represents the genomic
region (hg19 assembly) surrounding 1 Mb of the top SNP, while the y-axis represents the strength of the association in −log10(P-value).
Fig. S11). In the developing fetus (34), BARX1 is highly enriched
in stomach expression, when compared to the heart, intestine,
kidney, lung and adrenal gland (Supplementary Material,
Fig. S12). Moreover, BARX1 also has H3K36me3 marks in the fetal
and adult stomach (Supplementary Material, Fig. S13). For this
BARX1 locus, we genotyped the top SNP rs1933683 and observed
an OR for IHPS of 1.19 (P = 1.20 × 10−2) in the replication phase
(Table 1; Supplementary Material, Table S1). When the results
from the discovery and replication phases were meta-analyzed,
the summary OR for IHPS was 1.34 (P = 3.05 × 10−9) (Table 1;
Supplementary Material, Table S1).
We were not able to create a functional assay on the 13q21.31
locus for the US replication phase cohorts. Moreover, its high
missingness (0.03), non-significant P-value (P = 0.44) and oppo-
site direction of effect in the Swedish replication cohort com-
pared with the discovery phase cohorts (Supplementary Mate-
rial, Table S1), allied to the unavailability of good proxies (high
r2 and low P-value) for the top SNP, rs12870105, (Supplementary
Material, Table S2; Fig. S9) precluded us from evaluating this
signal further.
In our meta-analysis constrained to European ancestry
samples, we applied a fixed-effects model assuming that the
underlying allelic effect is the same in each population (Table 1;
Supplementary Material, Table S1). Adding the Hispanic Whites,
we may no longer assume that each population has the same
underlying allelic effect. The trans-ethnic meta-analysis, where
we allow a random effect to account for differences in allelic
effect betweenHispanicWhites and European ancestry samples,
show that we have decreased power to detect effects for variants
with substantial heterogeneity between the two ethnic groups,
namely the variants at 3q25.1 and 5q35.1 (Supplementary
Material, Table S1).
Genetic correlation
As a way to identify possible biomarker(s) associated with IHPS,
we sought to determine the genetic correlation of the IHPS
genome-wide meta-analysis results versus results for GWAS
of circulating metabolites (38) by using the LD score regression
method (25,26,30). We detected a nominally significant (P < 0.05)
positive genetic correlation with high-density lipoprotein (HDL)
cholesterol and APOA1, and a negative correlation with very
low-density lipoprotein cholesterol (Supplementary Material,
Table S3). To address the possibility that these genetic corre-
lations were mainly driven by the APOA gene cluster locus,
we removed the IHPS association results from this locus
(chr11:116.5–117.5 Mb, hg19 assembly). However, the results
did not change significantly (Supplementary Material, Table S4).
Although these findings were not statistically significant when
corrected for the number of metabolites tested (N = 79), a link
between lipid levels and risk of IHPS is consistent with previous
results. More specifically, characteristics of the IHPS locus on
chromosome 11q23.3 near APOA1 (10) suggest a functional
mechanism related to cholesterol levels, and allied to our
reported inverse relationship between levels of circulating total
cholesterol in neonates and IHPS risk (10).
Heritability
In the US non-Hispanic Whites of European ancestry replication
cohort, the six confirmed IHPS SNPs jointly explained 5.2% of
the variance in liability to IHPS, with children in the top 5%
of the polygenic risk score (PRS) distribution being at 8.45-fold
increased risk compared with the bottom 5%. Using the LD
score regression method (25,26) on our IHPS discovery phase
genome-widemeta-analysis results, we estimated the IHPS-SNP
heritability to be 30% ± standard error 6%. A similar SNP her-
itability estimate was determined with genome-wide complex
trait analysis (GCTA) (25% ± 4%) (27).
Discussion
In what we believe is the largest genetic study of IHPS so far,
we identified and replicated six independent genomic loci, out
of which two, on chromosomes 2p21 and 9q22.32, are reported
here for the first time (Table 1).
The new locus on chromosome 2p21 showed the strongest
IHPS association with an OR = 2.32. Among the genes at the
locus, EML4 (echinoderm microtubule-associated protein like-4)
andMTA3 (metastasis associated 1 familymember 3) are actively
transcribed in the fetal and adult stomach. Mutations in both
of these genes have been associated with tumor progression
and metastasis in various cancers. Notably, knockdown ofMTA3
expression has been associated with gastroesophageal junction
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/article-abstract/28/2/332/5114288 by R
oyal Library C
openhagen U
niversity user on 08 January 2020
336 Human Molecular Genetics, 2019, Vol. 28, No. 2
cancer (39) and, therefore, onemight speculatewhether aberrant
regulation of MTA3 could also cause congenital malformations
of the esophagus. A higher reported incidence of hypertrophic
pyloric stenosis in esophageal atresia patients (40) supports
this hypothesis. Moreover, reports on the association between
congenital malformations and increased cancer risk suggest a
shared etiology (41–45).
The gene BARX1 on chromosome 9q22.32 encodes a home-
obox transcription factor BARX1, which is specifically expressed
in both the adult and fetal human stomach.Themouse homolog,
Barx1, is essential to the formation of the stomach in the devel-
oping mouse embryo (46). The pyloric sphincter is absent in
Barx1 null mice (47), while ectopic expression of Barx1 in the
developing intestine induces smooth muscle of the stomach
type (48). Our association signal at the BARX1 locus suggests
that this homeobox transcription factor also plays an essential
role in the development of the gastrointestinal tract in humans.
Further support is found in familial syndromes involving dupli-
cations of the 9q22.1-9q31 region. This region harbors the BARX1
gene and these syndromes often include IHPS as part of the
clinical presentation (49,50). This is a good example of a GWAS
investigating isolated cases helping to identify the gene involved
in a specific condition in a syndrome associated with a larger
genomic region. As a way forward in the understanding of the
pathophysiology of IHPS, GWAS can give robust results that are
in line with observations from various syndromic cases (8).
NKX2-5 still remains the most obvious candidate causal gene
at the 5q35.1 IHPS locus due to being an eQTL gene for the IHPS-
associated SNPs and due to its causal role in the development of
the pyloric sphincter (51–53).
A positive genetic correlation of IHPS with HDL cholesterol
and APOA1, and a negative correlation with low-density lipopro-
tein (LDL) cholesterol were detected in this study, while our
previous study (10) found that umbilical cord blood from new-
borns who later presented with IHPS had lower levels of total
cholesterol compared with matched controls. Other observa-
tions from the literature suggest cholesterol as an important
factor in IHPS risk. For example, children with Smith–Lemli–
Opitz syndrome, an inborn defect of cholesterol biosynthesis,
have markedly increased risk of IHPS (54,55). IHPS risk is also
known to be associated with bottle feeding (7,56,57), and bottle
feeding is associated with decreased total and LDL cholesterol
levels in infancy (58). However, we should stress that our results
do not demonstrate cholesterol as a causal risk factor for IHPS
nor we can answer at what stage of development this putative
risk is created. Also, our genetic correlation results must be
interpreted with caution, since the lipid genetics studies on
which the correlations are based on used adult participants,
whereas relatively little is known about the genetic regulation
of cholesterol levels in fetal life or in newborns. Nonetheless,
further studies addressing the possible mechanistic influence of
cholesterol levels on IHPS physiopathology are warranted. These
studies could, for example, be focused on the role of cholesterol
in nervous system development (59), since pyloric sphincter
smooth muscle tissue from IHPS patients has been found to be
deficiently innervated (60).
In this study, we estimated the heritability to be 30%. Even
though the SNP heritability estimate is about one-third of a
previous family based estimate of IHPS heritability (87%) on the
same background population (7), it is within its 95% confidence
interval (CI) in the model with a shared environmental compo-
nent.Nevertheless, theremay still be a genetic component of the
disease that is not captured by the genotyped and well-imputed
variants used in our meta-analysis.Whether IHPS genetic archi-
tecture is composed of common variants with small effect sizes
not detected with our current sample size, and/or rare vari-
ants not captured by genotyped arrays used, remains to be
answered (61).
This genetic study included the largest sample of IHPS cases
to date, with cohorts from three European ancestry populations
and one from Hispanics, amounting to a total of 3708 cases and
6769 controls. By imputing our data to the Haplotype Reference
Consortium (HRC) reference panel, we were able to analyze IHPS
association for all low frequency and common variants detected
in European ancestry populations. Further studies including,
e.g. fine mapping by targeted sequencing and/or by trans-ethnic
analysis, are needed to pinpoint the causative variant at each
locus. In addition, more research is needed to dissect possi-
ble shared pathological mechanisms between IHPS and other
diseases.
Taken together, our genome-wide meta-analysis of IHPS
establishes two new loci for the disease, explains an estimated
30% of disease heritability and supports a previously reported
link to lipid metabolism (10). Moreover, we were able to general-
ize the replicated IHPS loci to populations of different ancestry
and admixture. These results elucidate novel mechanistic
avenues of IHPS disease architecture, which warrant further
investigation.
Materials and Methods
Study design
We report on a discovery phase of genome-wide meta-analysis
of two IHPS GWAS cohorts comprising 1395 cases and 4438
controls. This was followed by a replication phase in which we
genotyped the genome-wide significant loci of the discovery
phase in two independent cohorts, amounting to a total of 1794
cases and 1875 controls of European ancestry, and further con-
firmed in 633 cases and 633 controls from a Hispanic population.
Subjects
The discovery phase comprised two case-control IHPS cohorts of
Danish ancestry. IHPS surgery-confirmed cases were identified
through the Danish National Patient Register, which includes
all hospital diagnoses and operations since 1977 (11,12). The
first cohort consists of 968 cases and 2407 controls, details of
which have been previously published (9). Briefly, eligible IHPS
cases comprised children that had a pyloromyotomy in their
first year of life, were singletons born in Denmark with parents
and grandparents born in Northwestern Europe, were born with
no severe pregnancy complications and did not have any other
major congenital malformations. The second IHPS cohort com-
prised 427 IHPS cases, with the same eligibility criteria as the
first cohort described above, and 2031 controls. All controls in
the discovery phase were defined as samples with the same
selection criteria as for the cases, but without any IHPS diagnosis
or surgery code. All samples from the discovery phase were
drawn from the Danish Neonatal Screening Biobank (13) or from
the biobank of the Danish National Birth Cohort (14), both of
which are part of the Danish National Biobank.
For the replication phase, we used 2313 IHPS cases and 2331
controls from the USA and 114 cases and 177 controls from
Sweden. The US cohort comprised de-identified DNA extracted
from archived newborn blood spots of babies delivered to New
York State residents during 1998–2005 andwas divided into three
subsamples, due to differences in sampling time and maternal
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race/ethnicity (Supplementary Material, Table S1). Replication
cohorts US 1 and US 2 included non-Hispanic Whites of Euro-
pean ancestry sampled at different times, andUS 3 included only
Hispanic Whites. Cases were identified from the population-
based New York State Congenital Malformations Registry. Con-
trols were a random sample of all New York State live births
frequency-matched by birth year and race/ethnicity to cases.
The Swedish cohort consisted of whole blood specimens or
skin biopsies from cases that had pyloromyotomy at a pediatric
surgery clinic and placenta specimens from non-malformed
controls born in 2006. This study was approved by the Research
Ethics Committee of the Capital Region (Copenhagen) and the
Danish Data Protection Agency. The Danish Scientific Ethics
Committee also granted exemption from obtaining informed
consent from participants as this research project was based on
genotyping samples from biobank material (H-3-2009-093). For
the replication cohorts, the ethics committees at the Karolinska
Institutet approved the use of the Swedish samples, while the
institutional review board at the New York State Department of
Health and National Institutes of Health Office of Human Sub-
jects Research Protection approved the use of the US samples.
Genotyping and quality control
The first (9) and second cohorts of the discovery phase were
genotyped using the Illumina Human660W-Quad v1 A and
Multi-Ethnic Global v2 A2 arrays, respectively. We applied the
following quality control steps in each cohort separately, in
order to sequentially remove (1) variant probes not uniquely
aligned to the genome, (2) variants not present in dbSNP v.146,
(3) variants with conflicting reference alleles between Illumina
and dbSNP, (4) variants with missingness >5%, (5) variants that
failed Hardy–Weinberg test at P < 1 × 10−6, (6) variants with
P < 0.01 in tests of differences in missingness between cases
and controls, (7) variants with batch effect at P-value < 1e−5 (we
had more than one genotyped batch of specimens per cohort),
(8) variants with minor allele frequency <1%, (9) specimens with
discordant sex between registry records and genotypes and (10)
specimens with missingness >2%. These quality controls steps
were done with PLINK v1.90b3o (15). We also removed related
individuals with an estimated kinship coefficient Phi > 0.05,
within and between the two discovery phase cohorts, using
KING (16) as implemented in VCFtools (17). European ancestry
outliers were removed using the R package SNPRelate v1.2.0 (18),
based on principal component analysis (PCA) values for all our
cases and controls when analyzed together with the European
samples from the Human Genome Diversity Project (19). Outliers
were defined as specimens with PCA1 or PCA2 values further
than six times the interquartile range from the mean PCA1 (or
PCA2) values. The PCA outliers removal procedure was repeated
until no more specimens were removed (two rounds sufficed).
After the quality control steps, we ended up with 968 cases
and 2407 controls genotyped at 521 521 variants for the first
cohort and 427 cases and 2031 controls genotyped at 779 286
variants for the second cohort, with a total genotyping success
rate of 99.8%.
Genotype imputation
After genotyping QC, we imputed unobserved genotypes with
phased haplotypes from the HRC panel (version r1.0) (20). Impu-
tation was done separately for the two discovery phase cohorts
on the imputation server at the Wellcome Trust Sanger Institute
(https://imputation.sanger.ac.uk/) using the positional Burrows–
Wheeler transform algorithm (21). Prior to imputation, phasing
at the server was done using SHAPEIT2 v2.r790 (22).
Association analysis
Association analysis of imputed autosomal SNPs with IHPS was
performed separately in each discovery phase cohort using logis-
tic regression on imputed SNP dosages that had an imputation
info score ≥ 0.8 and MAF > 1%, under an additive genetic model
using PLINK (15). After filtering, we meta-analyzed the 6 576 307
SNPs present in both discovery phase cohorts with an inverse
variance-based fixed effects model, as implemented in PLINK
(15). Regional association plots were created with LocusZoom
(23). To test for the presence of additional independent IHPS-
associated SNPs at each of the genome-wide significant loci, we
conditioned on the imputed allelic dose of each top SNPper locus
in each discovery phase cohort and meta-analyzed the results.
GWAS replication
The replication phase cohorts from the USA and Sweden
were genotyped at LGC Genomics using PCR-based KASP
genotyping chemistry assays. For the four new loci that
reached genome-wide significance in the discovery phase,
we prioritized the top variant at each locus for genotyping.
However, if the top variant was in a repeat region and/or had
significant homology to many regions in the human genome,
we chose an alternative variant that: (1) was typed on the array
in at least one of the discovery phase cohorts, (2) had high LD
(r2 > 0.8) to the top variant and (3) was genome-wide significant
in themeta-analysis of the discovery phase.Association analysis
of the GWAS replication SNPs was performed separately in
each replication phase cohort using logistic regression on
SNP genotypes, under an additive genetic model using PLINK
(15). Results obtained in the replication cohorts of European
ancestry were meta-analyzed via an inverse variance-based
fixed effects model, as implemented in PLINK (15). Two SNPs
were not genotyped in the US Hispanic cohort (rs6736913 and
rs12721025) because power to detect an association was low
based on expected allele frequencies in the 1000 Genomes
AMR population (37). GWAS replicated loci were defined as (1)
having P < 5 × 10−8 in the discovery phase and discovery plus
replication phases, (2) nominally significant associations in the
meta-analysis of the replication cohorts of European ancestry
(P < 0.05) and (3) having the same direction of effects in all
replication cohorts of European ancestry. Heterogeneity of the
SNP associations across cohorts was tested with the Cochran’s
Q statistic (24). Of note, the US Hispanic cohort was not used for
replication per se but for confirming, or not, the GWAS replication
SNPs in a population other than just European ancestry. We
also report a trans-ethnic inverse variance-based meta-analysis
with a random effect accounting for the potential difference
in underlying allelic effect between the US Hispanic cohort
and the European ancestry samples (Supplementary Material,
Table S1).
Heritability and genetic correlation
Heritability estimation of our IHPS meta-analysis GWAS was
done with two methods: the LD score regression method
(25,26) on the meta-analysis summary statistics and the
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GCTA-GREML method (27) (GCTA v1.24.735) on the individual-
level genotyped QC variants in each discovery phase cohort
and inverse-variance meta-analyzed. The heritability on
observed scale was transformed to the liability scale using gear
(28) (https://sourceforge.net/p/gbchen/wiki/Hong%20Lee’s%20
Transformation%20for%20Heritability/), with prevalence of IHPS
set to 0.002 (3). The proportion of variance explained by the top
replicated SNPs was calculated with the Nagelkerke’s coefficient
of determination (29) on the US non-Hispanic Whites of Euro-
pean ancestry replication cohort, as implemented in the RsqGLM
function in https://modtools.wordpress.com/2014/10/30/rsqglm/.
The IHPS PRS was computed as
∑
log(w)∗SNP, with w being the
OR for each of the replicated variants in the discovery phase
meta-analysis, while SNP is the genotype of the replicated
variants (coded 0 to 2) in the samples from the US replication
cohort. Missing genotypes were imputed to the mean US cohort
value for each SNP.
Genetic correlation of our IHPS meta-analysis GWAS with
GWAS of circulating metabolites (38) was done with LD score
regression method (25,26), as implemented in LD hub (30).
Histone marks in fetal and adult stomach and small
intestine
H3K36me3 marks in the fetal and adult stomach and small
intestine were obtained from the National Institute of Health
(NIH) Roadmap Epigenomics Mapping Consortium datasets
of observed ChIP-seq P-value signal tracks (31), available at
http://epigenomegateway.wustl.edu/browser/ (32). We chose
H3K36me3 as this was the only available histone mark tagging
the entire active transcribed regions (33) for our relevant
tissues. Genes were defined as having H3K36me3 marks if
these overlapped its RefSeq gene coordinates with P-value
signal < 5 × 10−8.
Fetal and adult tissue-specific gene expression
Fetal tissue-specific gene expression data (34) were downloaded
from NCBI Bioproject PRJNA270632 on January 9, 2018. Fetal
expression data were available from at least three specimens
and up to seven specimens for each tissue. Adult tissue-specific
gene expression data were obtained from the GTEx Portal on
January 9, 2018, GTEx Analysis Release V7 (35). Adult expression
data were available from at least five specimens and up to 564
samples for each tissue.
Supplementary Material
SupplementaryMaterial includes Tables S1–4, and Figures S1–13.
The genome-wide meta-analysis summary statistics are avail-
able at http://danishnationalbiobank.com/gwas.html.
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